Extended interval dosing with ocrelizumab in multiple sclerosis

F Novak, HM Bajwa, K Østergaard… - Multiple Sclerosis …, 2024 - journals.sagepub.com
Background: This study investigates clinical and biomarker differences between standard
interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in multiple …
相关文章

Extended interval dosing with ocrelizumab in multiple sclerosis

F Novak, HM Bajwa, K Østergaard… - Multiple Sclerosis …, 2024 - research.regionh.dk
BACKGROUND: This study investigates clinical and biomarker differences between
standard interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in …

Extended interval dosing with ocrelizumab in multiple sclerosis

F Novak, HM Bajwa, K Østergaard, JM Berg… - Multiple Sclerosis …, 2024 - pure.au.dk
Background: This study investigates clinical and biomarker differences between standard
interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in multiple …

Extended interval dosing with ocrelizumab in multiple sclerosis

F Novak, HM Bajwa, K Østergaard… - Multiple sclerosis …, 2024 - pubmed.ncbi.nlm.nih.gov
Background This study investigates clinical and biomarker differences between standard
interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in multiple …

Extended interval dosing with ocrelizumab in multiple sclerosis.

F Novak, HM Bajwa, K Østergaard, JM Berg… - Multiple Sclerosis …, 2024 - europepmc.org
This study investigates clinical and biomarker differences between standard interval dosing
(SID) and extended interval dosing (EID) of ocrelizumab therapy in multiple sclerosis (MS) …

Extended interval dosing with ocrelizumab in multiple sclerosis

F Novak, HM Bajwa, K Østergaard, JM Berg… - ikm.ku.dk
BACKGROUND: This study investigates clinical and biomarker differences between
standard interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in …

Extended interval dosing with ocrelizumab in multiple sclerosis.

F Novak, HM Bajwa, K Østergaard… - Multiple Sclerosis …, 2024 - search.ebscohost.com
Background: This study investigates clinical and biomarker differences between standard
interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in multiple …

Extended interval dosing with ocrelizumab in multiple sclerosis

F Novak, HM Bajwa, K Østergaard… - Multiple …, 2024 - portal.findresearcher.sdu.dk
Background: This study investigates clinical and biomarker differences between standard
interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in multiple …

Extended interval dosing with ocrelizumab in multiple sclerosis

F Novak, HM Bajwa, K Østergaard, JM Berg… - Multiple Sclerosis …, 2024 - vbn.aau.dk
BACKGROUND: This study investigates clinical and biomarker differences between
standard interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in …